Biopharmaceutical Production Manager
About the job
- A bachelor's degree in Chemical Engineering, Mechanical Engineering, Biomedical Engineering, or another engineering or Biotechnology field.
- At least 7 years of experience in biopharmaceutical, biotechnology, or a related technology-driven industry.
- At least 3 years of management experience overseeing both direct and indirect reports.
- A demonstrated commitment to quality and compliance with a proven track record.
- Carry out tasks and interactions in accordance with GSK's core values: Accountability for Impact, Ambition for Patients, and Doing the Right Thing.
- Follow GSK's leadership expectations by focusing on priorities, motivating others, and supporting team growth to encourage high performance.
- Partner with NPI leads and support team managers to implement new products and equipment successfully.
- Manage four-shift operations in a 24/7 facility, overseeing production supervisors, specialists, and front-line staff.
- Ensure compliance with manufacturing, safety, and environmental regulations, including GSK QMS/EHS, CFR/cGMP, OSHA, and local, state, and federal requirements.
- Oversee documentation practices, approve batch documents, maintain compliant SOPs and logbooks, and ensure sufficient data-integrity controls are in place.
- Set departmental priorities using operational data and staff capacity.
- Meet department and site KPIs for safety, quality, and supply.
- Approve safety and compliance investigations and promote transparency and a values-driven culture.
- Hold teams accountable for cross-functional activities involving engineering, validation, and technology-transfer studies.
- Recommend updates to digital platforms.
- Develop workforce plans for staff development and performance management.
- Define production and staffing requirements to meet schedules.
- A master's degree in biological sciences or an engineering discipline.
- Five or more years of experience in large-scale manufacturing.
- Proficient verbal and written communication abilities and the capacity to collaborate effectively within a team environment.
- Hands-on operations experience, previous people-leadership experience, and participation in responsibilities beyond production operations.
- Outstanding interpersonal and leadership skills, with strong influence and relationship-building capabilities focused on teamwork.
About the company
GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.
Company Size
10,001+
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
1891
Get referred to GSK
See people who can refer or advise you
Simplify's Take
What believers are saying
- Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
- GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
- Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.
What critics are saying
- Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
- Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
- Zantac appeals and a securities case still threaten cash, disclosures, and management focus.
What makes GSK unique
- GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
- Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
- GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Company News
GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a biopharmaceutical manufacturing and research hub, creating over 300 jobs in the next five years, Pennsylvania Governor Josh Shapiro's office announced on Friday. The expansion will combine drug manufacturing, research and development, quality testing, and digital operations in Montgomery County. Construction is planned to begin in 2027 and will support clinical and commercial production of biologic medicines. The project will include a commercial-scale biologics manufacturing facility, a research pilot plant, and a centralised quality-control laboratory. It will also retain approximately 4,500 existing full-time jobs in Pennsylvania. Combined with GSK's previously announced Lancaster County facility, the company's planned investment in Pennsylvania totals nearly $1.7 billion.
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs. Posted on October 9, 2026 · Last updated: October 9, 2026 GSK to invest over $800 million in Pennsylvania biopharma hub, create 300 jobs. GSK's major expansion in Pennsylvania. Overview of the investment. Oct 9 (Reuters) - GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a new biopharmaceutical manufacturing and research hub, creating more than 300 jobs over the next five years, Pennsylvania Governor Josh Shapiro's office said on Friday. Key features of the new biopharma hub. * The investment will establish a site that combines drug manufacturing, research and development, quality testing and digital operations in Montgomery County. * GSK said construction is planned to begin in 2027 and the project will support both clinical and commercial production of biologic medicines. * The expansion is expected to create more than 300 new jobs and retain about 4,500 existing full-time jobs in Pennsylvania. * The company said the project will include a new commercial-scale biologics manufacturing facility, a research pilot plant and a centralized quality-control laboratory. Economic impact and incentives. * Pennsylvania officials said GSK will be eligible for state manufacturing tax incentives tied to the investment. * The Upper Merion expansion and GSK's previously announced Lancaster County facility project together represent nearly $1.7 billion of planned investment in Pennsylvania, according to state officials. * GSK, whose U.S. headquarters is in Philadelphia, said the expansion will help accelerate the development and supply of future medicines. Reporting credits. (Reporting by Sahil Pandey in Bengaluru; Editing by Anil D'Silva) Key takeaways. * GSK's $800M-plus expansion in Upper Merion expands capabilities across manufacturing, R&D, QC and digital operations and is part of a broader $1.7B investment in PA alongside Lancaster project. * The project supports both clinical and commercial biologic production, with construction slated for 2027, and helps retain more than 4,500 existing Pennsylvania full-time jobs. * State incentives - including manufacturing tax credits - and prior GSK investments in Lancaster contribute to reinforcing Pennsylvania's life-sciences leadership. Frequently asked questions. What is GSK investing in Pennsylvania? How many jobs will GSK's investment create in Pennsylvania? What facilities will be included in GSK's Upper Merion expansion? When is construction expected to begin for GSK's biopharma hub? What incentives is GSK eligible for with this investment?
GSK plans more than $800 million expansion in Pennsylvania. The Montgomery County project is expected to add about 300 jobs over the next five years. Published Oct 9, 2026, 2:46 PM EDT GSK plc (GSK) plans to invest more than $800 million to expand its operations in Montgomery County, Pennsylvania, with the project expected to add about 300 jobs over the next five years. Discover more Ethereum investment guide Stablecoin investment platform Accept Payments The investment will expand GSK's operations in Pennsylvania. The expansion is planned over the next five years, with the new jobs tied to the company's Montgomery County operations. John Kim. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to [email protected].
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs. Oct 9 (Reuters) - GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a new biopharmaceutical manufacturing and research hub, creating more than 300 jobs over the next five years, Pennsylvania Governor Josh Shapiro's office said on Friday. - The investment will establish a site that combines drug manufacturing, research and development, quality testing and digital operations in Montgomery County. - GSK said construction is planned to begin in 2027 and the project will support both clinical and commercial production of biologic medicines. - The expansion is expected to create more than 300 new jobs and retain about 4,500 existing full-time jobs in Pennsylvania. - The company said the project will include a new commercial-scale biologics manufacturing facility, a research pilot plant and a centralized quality-control laboratory. - Pennsylvania officials said GSK will be eligible for state manufacturing tax incentives tied to the investment. - The Upper Merion expansion and GSK's previously announced Lancaster County facility project together represent nearly $1.7 billion of planned investment in Pennsylvania, according to state officials. - GSK, whose U.S. headquarters is in Philadelphia, said the expansion will help accelerate the development and supply of future medicines. (Reporting by Sahil Pandey in Bengaluru; Editing by Anil D'Silva)
Chai Discovery announces collaboration with GSK following successful wet-lab evaluation. SAN FRANCISCO-(BUSINESS WIRE)-Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with GSK. Click here to view original post